Sarasota, FL -- (SBWIRE) -- 12/18/2018 -- Zion Market Research has published a new report titled "Personalized Medicine Market by Therapeutic Area (Oncology, Neurology, Cardiology, Antiviral, Psychiatry, and Others), by Application (Companion Diagnostics, Health Informatics, Biomarker Identification, and Clinical Research Applications), by End-User (Hospitals, Molecular Diagnostic Laboratories and Testing Facilities, Academic Institutes, Clinical Care and Research Laboratories, Contract Research Organizations, Bio and Health Informatics Companies, and Others), and by Technology (Pharmacogenomics, Metabolomics, Pharmacoproteomics, Pharmacogenetics, Stem Cell Therapy, Pharmacodynamics, Point of Care, and Pharmacokinetics): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017–2024". According to the report, the global personalized medicine market was valued at approximately USD 1577 million in 2017 and is expected to generate revenue of around USD 3466 million by 2024, growing at a CAGR of around 11.9% between 2018 and 2024.

Request Free Sample Report @ https://www.zionmarketresearch.com/sample/personalized-medicine-market

Personalized medicines, also known as individualized medicines or precision medicines, is an evolving field used by physicians where diagnostic tests are performed to identify the biological markers. This helps in the identification of medical treatment that works best for an individual. Personalized healthcare can detect diseases at an early stage and helps in increasing the efficiency, quality, and accessibility. Personalized medicines enhance the healthcare system and increase the target approach that requires molecular information of a patient instead of sticking to a generic treatment. Personalized medicine is likely to reduce the burden of diseases by targeting treatment and prevention effectively. These medicines improve the ability to predict and differentiate the diagnosis of diseases, better therapy responses, reduced severity of illness, short timelines for product development, and increased success rates. These medicines reduce healthcare expenditures with a quick and reliable selection of effective therapy for patients and minimize the costs associated with inefficient treatment.

The global personalized medicine market is primarily driven by the rising healthcare expenditure, which, in turn, leads to the need for effective diagnosis and treatment procedure for cancer and other life-threatening diseases. Increased use of combination for diagnostics and development of companion diagnostics, next-generation sequencing, and retails clinics enhance this market's growth. Increase in the adoption of next-generation sequencing by clinicians and growth in regulatory and reimbursement policies also support this market's development. Introduction of novel drugs and the use of highly accurate and sensitive techniques for diagnosis are expected to increase the penetration rates of the personalized medicine market in the near future.

Inquiry more about this report @ https://www.zionmarketresearch.com/inquiry/personalized-medicine-market

By therapeutic area, the personalized medicine market is segmented into oncology, neurology, cardiology, antiviral, psychiatry, and others. By application, this market is segmented into biomarker identification, clinical research, companion diagnostics, and health informatics. By end-user, this market is segmented into contract research organizations, hospitals, bio and health informatics companies, molecular diagnostic laboratories and testing facilities, academic institutes, clinical care, and research laboratories, and others. By technology, the personalized medicine market includes pharmacogenomics, metabolomics, pharmacoproteomics, pharmacogenetics, stem cell therapy, pharmacodynamics, pharmacokinetics, and point of care.

North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa are the regional segments of the global personalized medicine market. North America is expected to remain the leading region over the forecast period, which would be closely followed by Europe. The Asia Pacific is likely to grow moderately and the Middle East and Africa, and Latin America are expected to show considerable growth over the forecast time period.

Some key players of the global personalized medicine market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Qiagen, AstraZeneca Plc., Merck & Co., Inc., Siemens Healthcare GmbH, Vertex Pharmaceuticals Incorporated, and Becton, Dickinson, and Company, among others.

Browse the full "Personalized Medicine Market" Report at https://www.zionmarketresearch.com/report/personalized-medicine-market

This report segments the global personalized medicine market as follows:

Global Personalized Medicine Market: Therapeutic Area Segment Analysis

Oncology
Neurology
Cardiology
Antiviral
Psychiatry
Others

Global Personalized Medicine Market: Application Segment Analysis

Companion Diagnostics
Health Informatics
Biomarker Identification
Clinical Research

Global Personalized Medicine Market: Technology Segment Analysis

Pharmacogenomics
Metabolomics
Pharmacoproteomics
Pharmacogenetics
Stem cell therapy
Pharmacodynamics
Point of care
Pharmacokinetics

Global Personalized Medicine Market: End-User Segment Analysis

Hospitals
Molecular Diagnostic Laboratories and Testing Facilities
Academic Institutes, Clinical Care, and Research Laboratories
Contract Research Organizations
Bio and Health Informatics Companies
Others

Global Personalized Medicine Market: Regional Segment Analysis

North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa